Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy

• Status: Recruiting
• Trial end date: 2024-06-30
• Target enrollment: 0
• Participant gender: All

Summary

In patients with coronary heart disease who were treated with PCSK9 inhibitor evolocumab for intensive lipid-lowering therapy, the changes of retinal microvessels were measured with OCTA (Optical Coherence Tomography Angiography)before and after the treatment. The specific indicators included retinal microvessel diameter, macular area，optic disc vascular density and FAZ(Foveal Avascular Zone)area, etc., to clarify the effect of evolocumab on retinal microvessels after intensive lipid-lowering therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zibo Central Hospital
• Treatments: Evolocumab; Hydroxymethylglutaryl-CoA Reductase Inhibitors

Criteria

Inclusion Criteria:

1. Age 50-75 years old, gender unlimited;

2. Diagnosed as coronary atherosclerotic heart disease

3. The informed consent for the study has been signed

Exclusion Criteria:

1. Those who are unable to cooperate with the examination;

2. Poor imaging quality of refractive interstitial opacity;

3. Macular edema or complicated with macular membrane and senile macular degeneration;

4. Have a history of previous fundus surgery;

5. Those with eye diseases that can cause changes in the microvessels of the fundus;

6. Abnormal elevated intraocular pressure;

7. Moderate or above refractive error (≥ ± 3 diopters)

8. People with cognitive impairment, material dependence, and serious mental illness;

9. Those who do not cooperate with follow-up;

10. Those who participate in other clinical trials at the same time